1) Free: Double jeopardy takes down Sanofi’s cabazitaxel use patent as UPC’s Munich LD revokes after EPO BoA affirmance

If patents are challenged in the European Patent Office (EPO) during the nine-month opposition window, they can nevertheless become the subject of revocation (counter)claims in the Unified Patent Court (UPC). If one forum upholds and another invalidates, the patent is revoked with respect to the relevant countries. That possibility increases the risk to patentees.

2) Premium: Teva removes more than 200 patents from U.S. FDA’s Orange Book: win for FTC

Following President Trump’s promise to lower the cost of drugs and a United States Federal Trade Commission investigation into a patent portfolio owned by Teva, the Israeli pharma company has asked the Food and Drug Administration to remove more than 200 improper patent listings related to asthma, diabetes, and COPD drugs, and epinephrine autoinjectors, from…

3) Premium: U.S. appeals court to Apple: now prove the value of your IP in district court (for the first time since the Samsung patent spat)

An appellate ruling that largely upheld contempt sanctions imposed on Apple will now lead to further proceedings in district court.

4) Free summary, otherwise premium: Encourage FRAND SEP licensing negotiations through patent pools, intermediaries: The World Bank recommends to low, middle-income nations

The World Bank’s first-ever report on standards has issued several recommendations to low and middle-income nations on how they can leverage standard-essential patents to propel their economies, pointing to China and the Republic of Korea as model examples.